|
Orthologous residues
|
|
ULK1 (human): S758‑p, ULK1 (mouse): S757‑p, ULK1 (rat): S757‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
bone cancer
|
|
Relevant cell lines - cell types - tissues:
293T (epithelial), U2OS (bone cell)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
mTOR (human)
|
siRNA inhibition of enzyme, pharmacological inhibitor of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
starvation medium
|
|
|
|
decrease
|
|
|
serum starvation
|
|
|
|
decrease
|
|
|
Ca(2+)
|
starvation medium
|
|
|
no effect upon treatment-induced decrease
|
|
|
rapamycin
|
|
|
|
decrease
|
|
|
siRNA
|
|
|
|
decrease
|
siRNA mTOR
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
autophagy, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
AMPKA1 (human)
|
|
Induces
|
|
|
co-immunoprecipitation
|
|